PressDecember 28, 2022 Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
PressDecember 28, 2022 Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease
PressDecember 26, 2022 Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
PressDecember 26, 2022 Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
PressDecember 22, 2022 Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression
PressDecember 20, 2022 Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
PressDecember 19, 2022 The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
PressDecember 19, 2022 Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
PressDecember 19, 2022 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
PressDecember 15, 2022 PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
PressDecember 15, 2022 FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
PressDecember 15, 2022 Filament Health and Psyence Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
PressDecember 15, 2022 Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
PressDecember 14, 2022 Mindbloom Announces Rollout of Ketamine Telehealth Employee Benefits Program with Kennedy Care, 15Five
BlogDecember 14, 2022 Core One Labs : Subsidiary Vocan Biotechnologies Achieves Development Milestones
PressDecember 14, 2022 Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
PressDecember 14, 2022 Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th
PressDecember 14, 2022 Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor
